Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmony: Efruxifermin in Non-Cirrhotic NASH
NCT04767529Phase 2Completed
- Sponsor
- Akero Therapeutics
- Start
- Feb 2021
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), sponsored by Akero Therapeutics. Started Feb 2021; status: completed.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04767529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767529.